28
前列 前列腺腺肥大 肥大 前列 前列腺腺肥大 肥大

前列腺肥大 - ntcma.orgntcma.org/a10_pl_B/antony/ed/ed/bph.pdf · BPH使用bethanechol 之原則: 1. BPH病人建議不宜直接使用bethanechol ,若已服用finasteridefinasteride或或α-blocker3blocker

  • Upload
    lethuy

  • View
    237

  • Download
    9

Embed Size (px)

Citation preview

  • McNeal

  • Gross appearanceappearance of Hyperplastic prostateprostate

  • Mcneal

    20 65% 25% 10%70 50%

  • 2-5 cc 2 5 cc, 2cc 0.5cc

    (0.15mg/ml)

  • 80 90%80 90%

  • (5-alpha reductase)

  • 755 0-7 8-19 20-35 20 35

  • 51

    Q1Q1

    0 1 2 3 4 5

    Q22 0 1 2 3 4 5

    Q3Q3

    0 1 2 3 4 5

    Q4

    0 1 2 3 4 5

    Q5

    0 1 2 3 4 5

    Q6 0 1 2 3 4 5

    Q7 5Q7

    0 1 2 3 45

    (

  • 0-7 8 198-1920-35 20 35

  • ::::

    Adapted from Nordling J et al. In Benign Prostatic Hyperplasia. Plymouth, United Kingdom: Health Publication, 2001:107-166.

    Slide I.2

  • BPHBPHBPHBPH10

    8

    9.0 40 ml >40 ml

    (n=458)

    66.1

    5.6

    4 3.6

    3.1

    22.3

    0(p

  • BPHBPHBPHBPH80

    70 6671

    66

    (n=90)

    60

    50 47

    40

    30

    %

    20

    10

    0

    Adapted from Sells H et al Br J Urol Int 2000;85:440-445.

    Slide II.4

  • ICBPH guideline

    Adapted from Fifth International Consultation 2001 on BPH. In Benign Prostatic Hyperplasia. Plymouth, United Kingdom: Health Publication, 2001:519-535.

    Slide IV.3

  • Slide II.1

  • ( D i T i T l i )-( eg. Doxazosin, Terazosin, Tamsulosin)

    5 -Proscar (finasteride)Avodart (dutasteride)

  • doxazosin finasteride

    PROSCAR, finasteride)(AUR)

    x

  • BPHBPHbethanecholbethanechol BPHBPHbethanechol bethanechol

    1. BPHbethanecholfinasteride blocker 3finasteride-blocker 3

    2. on Foley

    detrusor x

  • BPHBPHbethanecholbethanechol BPHBPHbethanechol bethanechol

    3. DM1

    4. DMAUR4. DMAUR

    5. NBneurogenic bladderurinary retention on Foleyretention on Foley

    x